

Supplementary Material

Supplementary Table 1. Signs and symptoms in ambulatory patients

Supplementary Table 2. Signs and symptoms in hospitalized patients

Supplementary Table 3. Baseline and follow-up characteristics of survivors and non-survivors

Supplementary Table 4. Survival analysis of patients undergoing IMV

Supplementary Table 5. Survival analysis of patients admitted to ICU

Supplementary Table 6. Survival analysis of non-pregnant/puerperal adults

Supplementary Table 7. Survival analysis of children and adolescents

Supplementary Table 8. Survival analysis of pregnant women

Supplementary Table 9. Unadjusted Cox regression models for mortality in all patients, ambulatory, hospitalized, non-critical, and critical patients

Supplementary Table 10. Mortality risk in patients undergoing IMV

Supplementary Table 11. Mortality risk in patients admitted to ICU

Supplementary Table 12. Mortality risk in non-pregnant/puerperal adults

Supplementary Table 13. Mortality risk in children and adolescents

Supplementary Table 14. Mortality risk in pregnant women

Supplementary Table 15. E-values for the general population, ambulatory, hospitalized, non-critical, and critical patients

Supplementary Table 16. E-values for IMV, ICU, Non-pregnant/puerperal adults, and children and adolescents

Supplementary Table 17. Baseline characteristics of patients with complete dates of antiviral initiation

Supplementary Table 18. Survival analysis of early and late use of antivirals

Supplementary Figure 1. Timing of symptom onset, initiation of antiviral, and hospitalization

Supplementary Figure 2. Comparison of hospitalization rates between early and late use of antivirals

Supplementary Table 1. Signs and symptoms in laboratory-confirmed COVID-19 ambulatory patients treated with antivirals and/or antibiotics in 603 accredited medical units in Mexico City between February 24, 2020 and September 14, 2020.

	No antiviral/ antibiotic n=98060	Acyclovir n=30	Amantadine n=282	Lopinavir- Ritonavir n=8	Osetamivir n=3187	Rimantadine n=48	Zanamivir n=19	Antibiotic only n=8268	Total n=109902	P value
Number of signs and symptoms, mean (SD)	5.8 (3.8)	6.8 (3.3) ^a	7.2 (3.6)	7.9 (5.3)	7.8 (3.3) ^a	7.6 (3.2) ^a	6.7 (4.6)	7.0 (3.5) ^a	5.9 (3.8)	<.001
Fever	52966 (54)	21 (70)	169 (59.9)	5 (62.5)	2465 (77.3)	31 (64.6)	13 (68.4)	5471 (66.2)	61141 (55.6)	<.001
Cough	65216 (66.5)	19 (63.3)	216 (76.6)	6 (75)	2583 (81)	34 (70.8)	15 (78.9)	6071 (73.4)	74160 (67.5)	<.001
Sore throat	41927 (42.8)	12 (40)	144 (51.1)	3 (37.5)	1611 (50.5)	24 (50)	5 (26.3)	4388 (53.1)	48114 (43.8)	<.001
Shortness of breath	19091 (19.5)	11 (36.7)	63 (22.3)	4 (50)	1010 (31.7)	12 (25)	8 (42.1)	2237 (27.1)	22436 (20.4)	<.001
Irritability	16364 (16.7)	5 (16.7)	70 (24.8)	2 (25)	720 (22.6)	11 (22.9)	7 (36.8)	1593 (19.3)	18772 (17.1)	<.001
Diarrhea	22096 (22.5)	10 (33.3)	86 (30.5)	3 (37.5)	981 (30.8)	12 (25)	7 (36.8)	2456 (29.7)	25651 (23.3)	<.001
Chest pain	23150 (23.6)	9 (30)	87 (30.9)	2 (25)	1158 (36.3)	19 (39.6)	7 (36.8)	2494 (30.2)	26926 (24.5)	<.001
Chills	32621 (33.3)	14 (46.7)	139 (49.3)	6 (75)	1585 (49.7)	27 (56.3)	5 (26.3)	3482 (42.1)	37879 (34.5)	<.001
Headache	67181 (68.5)	21 (70)	202 (71.6)	6 (75)	2575 (80.8)	31 (64.6)	13 (68.4)	6022 (72.8)	76051 (69.2)	<.001
Myalgias	47106 (48)	23 (76.7)	175 (62.1)	5 (62.5)	2053 (64.4)	32 (66.7)	8 (42.1)	4993 (60.4)	54395 (49.5)	<.001
Arthralgias	42161 (43)	18 (60)	155 (55)	4 (50)	1881 (59)	31 (64.6)	6 (31.6)	4530 (54.8)	48786 (44.4)	<.001
Abrupt deterioration	38549 (39.3)	15 (50)	157 (55.7)	5 (62.5)	1923 (60.3)	24 (50)	6 (31.6)	4471 (54.1)	45150 (41.1)	<.001
Rhinorrhea	28354 (28.9)	6 (20)	107 (37.9)	4 (50)	1079 (33.9)	23 (47.9)	6 (31.6)	2744 (33.2)	32323 (29.4)	<.001
Polypnea	7412 (7.6)	3 (10)	37 (13.1)	3 (37.5)	381 (12)	3 (6.3)	3 (15.8)	859 (10.4)	8701 (7.9)	<.001
Vomit	6406 (6.5)	2 (6.7)	18 (6.4)	0 (0)	309 (9.7)	6 (12.5)	1 (5.3)	696 (8.4)	7438 (6.8)	<.001
Abdominal pain	11502 (11.7)	3 (10)	49 (17.4)	0 (0)	646 (20.3)	8 (16.7)	4 (21.1)	1065 (12.9)	13277 (12.1)	<.001
Conjunctivitis	12784 (13)	4 (13.3)	53 (18.8)	3 (37.5)	475 (14.9)	11 (22.9)	5 (26.3)	1315 (15.9)	14650 (13.3)	<.001
Cyanosis	2843 (2.9)	1 (3.3)	9 (3.2)	1 (12.5)	152 (4.8)	6 (12.5)	2 (10.5)	245 (3)	3259 (3)	<.001
Sudden onset of symptoms	32348 (33)	7 (23.3)	93 (33)	1 (12.5)	1359 (42.6)	19 (39.6)	7 (36.8)	3067 (37.1)	36901 (33.6)	<.001

Data expressed as frequency (%). P values were calculated by X^2 or One-way ANOVA.

a: Statistical difference with respect to No antiviral/antibiotic.

SD: Standard deviation

Supplementary Table 2. Signs and symptoms in laboratory-confirmed COVID-19 hospitalized patients treated with antivirals and/or antibiotics in 329 accredited medical units in Mexico City between February 24, 2020 and September 14, 2020.

	No antiviral / antibiotic n=16083	Acyclovir n=6	Amantadine n=37	Lopinavir- Ritonavir n=92	Osetamivir n=5227	Rimantadine n=13	Zanamivir n=20	Antibiotic only n=5475	Total n=26953	P value
Number of signs and symptoms, mean (SD)	7.9 (3.4)	6 (2.6)	7.9 (3.3)	6.6 (2.9) ^a	8.1 (3.4) ^a	8.8 (2.4)	9.4 (2.8)	6.9 (3.2) ^a	7.8 (3.4)	<.001
Fever	13045 (81.1)	4 (66.7)	29 (78.4)	76 (82.6)	4498 (86.1)	11 (84.6)	18 (90)	4298 (78.5)	21979 (81.5)	<.001
Cough	13151 (81.8)	5 (83.3)	29 (78.4)	61 (66.3)	4472 (85.6)	8 (61.5)	20 (100)	4300 (78.5)	22046 (81.8)	<.001
Sore throat	6918 (43)	0 (0)	15 (40.5)	28 (30.4)	2090 (40)	5 (38.5)	17 (85)	1853 (33.8)	10926 (40.5)	<.001
Shortness of breath	11970 (74.4)	3 (50)	22 (59.5)	62 (67.4)	4160 (79.6)	10 (76.9)	15 (75)	4264 (77.9)	20506 (76.1)	<.001
Irritability	3096 (19.3)	0 (0.0)	11 (29.7)	5 (5.4)	1273 (24.4)	3 (23.1)	6 (3)	932 (17)	5326 (19.8)	<.001
Diarrhea	3725 (23.2)	1 (16.7)	10 (27)	16 (17.4)	1199 (22.9)	3 (23.1)	6 (30)	1038 (19)	5998 (22.3)	<.001
Chest pain	6374 (39.6)	3 (50.0)	18 (48.6)	20 (21.7)	1821 (34.8)	6 (46.2)	8 (40)	1675 (30.6)	9925 (36.8)	<.001
Chills	6784 (42.2)	2 (33.3)	19 (51.4)	28 (30.4)	2031 (38.9)	6 (46.2)	12 (60)	1521 (27.8)	10403 (38.6)	<.001
Headache	11712 (72.8)	1 (16.7)	25 (67.6)	53 (57.6)	3773 (72.2)	9 (69.2)	16 (80)	3378 (61.7)	18967 (70.4)	<.001
Myalgias	10086 (62.7)	4 (66.7)	26 (70.3)	55 (59.8)	3021 (57.8)	11 (84.6)	16 (80)	3052 (55.7)	16271 (60.4)	<.001
Arthralgias	9631 (59.9)	4 (66.7)	24 (64.9)	44 (47.8)	2965 (56.7)	11 (84.6)	17 (85)	2899 (52.9)	15595 (57.9)	<.001
Abrupt deterioration	10442 (64.9)	5 (83.3)	23 (62.2)	61 (66.3)	3444 (65.9)	10 (76.9)	14 (70)	3311 (60.5)	17310 (64.2)	<.001
Rhinorrhea	3781 (23.5)	0 (0)	11 (29.7)	16 (17.4)	1204 (23)	4 (30.8)	5 (25)	944 (17.2)	5965 (22.1)	<.001
Polypnea	4565 (28.4)	0 (0)	9 (24.3)	10 (10.9)	1466 (28)	4 (30.8)	3 (15)	1110 (20.3)	7167 (26.6)	<.001
Vomit	1688 (10.5)	1 (16.7)	5 (13.5)	7 (7.6)	561 (10.7)	2 (15.4)	1 (5)	420 (7.7)	2685 (10)	<.001
Abdominal pain	2578 (16)	0 (0)	11 (29.7)	8 (8.7)	915 (17.5)	2 (15.4)	3 (15)	544 (9.9)	4061 (15.1)	<.001
Conjunctivitis	1493 (9.3)	0 (0)	2 (5.4)	4 (4.3)	487 (9.3)	0 (0)	1 (5)	304 (5.6)	2291 (8.5)	<.001
Cyanosis	1618 (10.1)	0 (0)	3 (8.1)	3 (3.3)	664 (12.7)	2 (15.4)	1 (5)	367 (6.7)	2658 (9.9)	<.001
Sudden onset of symptoms	5259 (32.7)	3 (50)	3 (8.1)	47 (51.1)	2472 (47.3)	7 (53.8)	9 (45)	2022 (36.9)	9822 (36.4)	<.001
Data expressed as frequency (%). P values were calculated by χ^2 or One-way ANOVA.										
a: Statistical difference with respect to No antiviral/antibiotic. SD: Standard deviation										

Supplementary Table 3. Baseline and follow-up characteristics of laboratory confirmed COVID-19 survivors and non-survivors who received medical attention in 688 accredited units in Mexico City between February 24, 2020 and September 14, 2020.

	Total population n=136855	Survivors n=125176	Non-survivors n=11679	P Value	
Sex					
Women	66683 (48.7)	62907 (50.3)	3776 (32.3)	<.001	
Men	70172 (51.3)	62269 (49.7)	7903 (67.7)		
Age, mean (SD)	44.2 (16.8)	42.5 (15.9)	62 (14.1)	<.001	
Age categories					
0-19 years	7558 (5.5)	7514 (6)	44 (0.4)	<.001	
20-29 years	20098 (14.7)	19974 (16)	124 (1.1)		
30-39 years	29434 (21.5)	28909 (23.1)	525 (4.5)		
40-49 years	29553 (21.6)	28084 (22.4)	1469 (12.6)		
50-59 years	24928 (18.2)	22298 (17.8)	2630 (22.5)		
60-69 years	15070 (11)	11840 (9.5)	3230 (27.7)		
70-79 years	7183 (5.2)	4731 (3.8)	2452 (21)		
80-89 years	2594 (1.9)	1540 (1.2)	1054 (9)		
90-99 years	419 (0.3)	270 (0.2)	149 (1.3)		
≥100 years	18 (0.01)	16 (0.01)	2 (0.001)		
Indigenous self-identification	713 (0.5)	639 (0.5)	74 (0.6)	.08	
Occupation					
Technical services	1916 (1.4)	1702 (1.4)	214 (1.8)	<.001	
Education	10006 (7.3)	9923 (7.9)	83 (0.7)		
Healthcare	17281 (12.6)	16954 (13.5)	327 (2.8)		
Agricultural activities	302 (0.2)	244 (0.2)	58 (0.5)		
Commerce	50450 (36.9)	47070 (37.6)	3380 (28.9)		
Other	24630 (18)	22383 (17.9)	2247 (19.2)		
Unemployed	5685 (4.2)	4539 (3.6)	1146 (9.8)		
Stay-at-home	26585 (19.4)	22361 (17.9)	4224 (36.2)		
Last-season flu vaccination	25691 (19.7)	24570 (20.7)	1121 (9.6)		<.001
Special populations					
Pregnancy	583 (0.9)	573 (0.9)	10 (0.3)	<.001	
Age during pregnancy, mean (SD)	29.8 (7.4)	29.8 (7.5)	32.7 (6)	.2	
Last-season flu vaccination	161 (27.6)	158 (27.6)	3 (30)	.9	
Pregnancy Age					
Early adolescent (≤14 years)	2 (0.3)	2 (0.3)	0 (0)	.2	
Late adolescent (15-19 years)	34 (5.8)	34 (5.9)	0 (0)		
Normal age (20-34 years)	404 (69.3)	398 (69.5)	6 (60)		

Advanced maternal age (≥ 35 years)	143 (24.5)	139 (24.3)	4 (40)	
Trimester of pregnancy				
First trimester	114 (19.6)	114 (19.9)	0 (0.0)	<.001
Second trimester	177 (30.4)	174 (30.4)	3 (30)	
Third trimester	292 (50.1)	285 (49.7)	7 (70)	
Puerperium	103 (0.2)	102 (0.2)	1 (0.03)	.9
Days of puerperium				
1 day	33 (32)	32 (31.4)	1 (100)	.2
2-7 days	33 (32)	33 (32.4)	0 (0)	
8-42 days	37 (35.9)	37 (36.3)	0 (0)	
Age during puerperium, mean (SD)	31.9 (9.7)	31.9 (9.7)	24	.5
Last-season flu vaccination	22 (21.4)	22 (21.6)	0 (0)	.6
Children and adolescents (<18 years)	5791 (4.2)	5751 (4.6)	40 (0.3)	<.001
Age, mean (SD)	10.9 (5.2)	10.9 (5.2)	7.5 (6.4)	<.001
Last-season flu vaccination	1213 (20.9)	1211 (21.1)	2 (5)	.01
Non-pregnant/puerperal adults (≥ 18 years)	130378 (95.3)	118750 (94.9)	11628 (99.6)	<.001
Age, mean (SD)	45.7 (15.5)	44.1 (14.7)	62.2 (13.7)	<.001
Last-season flu vaccination	25691 (19.7)	24570 (20.7)	1121 (9.6)	<.001
Comorbidities				
Diabetes	18229 (13.3)	14136 (11.3)	4093 (35)	<.001
COPD	1741 (1.3)	1184 (0.9)	557 (4.8)	<.001
Asthma	3035 (2.2)	2858 (2.3)	177 (1.5)	<.001
Immunosuppression	1758 (1.3)	1380 (1.1)	378 (3.2)	<.001
Hypertension	22185 (16.2)	17574 (14)	4611 (39.5)	<.001
HIV/AIDS	573 (0.4)	509 (0.4)	64 (0.5)	.02
Cardiovascular disease	2724 (2)	2128 (1.7)	596 (5.1)	<.001
Obesity	23848 (17.4)	21072 (16.8)	2776 (23.8)	<.001
Chronic kidney disease	2067 (1.5)	1298 (1)	769 (6.6)	<.001
Smoker	14727 (10.8)	13437 (10.7)	1290 (11)	.3
Time from symptom onset to medical attention	4.5 (3.9)	4.5 (3.8)	4.9 (3.9)	<.001
Baseline symptoms				
Fever	83120 (60.7)	73561 (58.8)	9559 (81.8)	<.001
Cough	96206 (70.3)	86484 (69.1)	9722 (83.2)	<.001
Sore throat	59040 (43.1)	54325 (43.4)	4715 (40.4)	<.001
Shortness of breath	42942 (31.4)	33762 (27)	9180 (78.6)	<.001
Irritability	24098 (17.6)	21767 (17.4)	2331 (20)	<.001
Diarrhea	31649 (23.1)	29141 (23.3)	2508 (21.5)	<.001
Chest pain	36851 (26.9)	32498 (26)	4353 (37.3)	<.001
Chills	48282 (35.3)	43660 (34.9)	4622 (39.6)	<.001

Headache	95018 (69.4)	86872 (69.4)	8146 (69.7)	.4
Myalgias	70666 (51.6)	63547 (50.8)	7119 (61.0)	<.001
Arthralgias	64381 (47)	57539 (46)	6842 (58.6)	<.001
Abrupt deterioration	62460 (45.6)	54794 (43.8)	7666 (65.6)	<.001
Rhinorrhea	38288 (28)	35677 (28.5)	2611 (22.4)	<.001
Polypnea	15868 (11.6)	12283 (9.8)	3585 (30.7)	<.001
Vomit	10123 (7.4)	8956 (7.2)	1167 (10)	<.001
Abdominal pain	17338 (12.7)	15639 (12.5)	1699 (14.5)	<.001
Conjunctivitis	16941 (12.4)	15965 (12.8)	976 (8.4)	<.001
Cyanosis	5917 (4.3)	4430 (3.5)	1487 (12.7)	<.001
Sudden onset of symptoms	46723 (34.1)	42636 (34.1)	4087 (35)	.04
Contact with confirmed COVID-19 case	70923 (51.8)	69506 (55.5)	1417 (12.1)	<.001
Type of treatment received				
No antiviral / antibiotic	114143 (83.4)	106792 (85.3)	7351 (62.9)	<.001
Antiviral only	4044 (3)	2980 (2.4)	1064 (9.1)	
Antibiotic only	13743 (10)	11788 (9.4)	1955 (16.7)	
Antiviral + antibiotic	4925 (3.6)	3616 (2.9)	1309 (11.2)	
Type of antiviral used				
Acyclovir	36 (0.03)	32 (0.03)	4 (0.03)	<.001
Amantadine	319 (0.2)	304 (0.2)	15 (0.1)	
Lopinavir-Ritonavir	100 (0.1)	75 (0.1)	25 (0.2)	
Oseltamivir	8414 (6.1)	6100 (4.9)	2314 (19.8)	
Rimantadine	61 (0.04)	54 (0.04)	7 (0.1)	
Zanamivir	39 (0.03)	31 (0.02)	8(0.1)	

Data expressed as frequency (%) or median (SD). P values were calculated by X^2 or Student's t-test.

SD: Standard deviation, COPD: Chronic obstructive pulmonary disease, HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome.

Supplementary Table 4. Survival analysis of laboratory-confirmed COVID-19 patients who underwent invasive mechanical ventilation (IMV) and were treated with antivirals and/or antibiotics in one of 197 accredited hospitals in Mexico City, between February 24, 2020 and September 14, 2020.

Group	Total	Deaths	Survivors	Survival	P value
Patients receiving IMV	6752	5346	1406	20.8%	-
Type of treatment					
No antiviral/antibiotic	3931	3240	691	17.6%	Reference
Antiviral only	507	431	76	15.0%	.001
Antibiotic only	1586	1087	499	31.5%	<.001
Antiviral + Antibiotic	768	621	147	19.1%	.3
Type of antiviral or antibiotic only					
No antiviral/antibiotic	3931	3240	691	17.6%	Reference
Acyclovir	2	2	0	0.0%	.6
Amantadine	7	7	0	0.0%	.5
Lopinavir-Ritonavir	23	16	7	30.4%	.1
Oseltamivir	1235	1019	216	17.5%	.2
Rimantadine	3	3	0	0.0%	.4
Zanamivir	5	5	0	0.0%	.9
Antibiotic only	1586	1087	499	31.5%	<.001
Treatment with oseltamivir					
No antiviral/antibiotic	3931	3240	691	17.6%	Reference
Oseltamivir	488	413	75	15.4%	.01
Antibiotic only	1586	1087	499	31.5%	<.001
Oseltamivir + Antibiotic	747	606	141	18.9%	.4
Data expressed as number of patients or percentual of survival. P values were calculated by Log-Rank test.					

Supplementary Table 5. Survival analysis of laboratory-confirmed COVID-19 patients treated with antivirals and/or antibiotics and admitted to one of 125 accredited intensive care units (ICU) in Mexico City, between February 24, 2020 and September 14, 2020.

Group	Total	Deaths	Survivors	Survival	P value
Patients admitted to ICU	2425	1475	950	39.2%	-
Type of treatment					
No antiviral/antibiotic	908	494	414	45.6%	Reference
Antiviral only	77	53	24	31.2%	.00
Antibiotic only	1011	610	401	39.7%	.02
Antiviral + Antibiotic	461	336	125	27.1%	<.001
Antiviral or antibiotic only					
No antiviral/antibiotic	908	494	414	45.6%	Reference
Acyclovir	1	1	0	0.0%	.08
Amantadine	2	0	2	100.0%	.20
Lopinavir-Ritonavir	29	17	12	41.4%	.40
Oseltamivir	506	371	135	26.7%	<.001
Antibiotic only	1011	610	401	39.7%	.02
Oseltamivir					
No antiviral/antibiotic	908	494	414	45.6%	Reference
Oseltamivir	66	48	18	27.3%	<.001
Antibiotic only	1011	610	401	39.7%	.02
Oseltamivir + Antibiotic	440	323	117	26.6%	<.001
Data expressed as number of patients or percentual of survival. P values were calculated by Log-Rank test.					

Supplementary Table 6. Survival analysis of laboratory-confirmed COVID-19 non-pregnant/puerperal adults treated with antivirals and/or antibiotics in 379 accredited medical units in Mexico City, between February 24, 2020 and September 14, 2020.

Group	Total	Deaths	Survivors	Survival	P value
Non-pregnant/puerperal adults	129837	11569	118268	91.1%	-
Type of treatment					
No antiviral/antibiotic	108213	7314	100899	93.2%	Reference
Antiviral only	3990	1063	2927	73.4%	<.001
Antibiotic only	13300	1945	11355	85.4%	<.001
Antiviral + Antibiotic	4875	1306	3569	73.2%	<.001
Type of antiviral or antibiotic only					
No antiviral/antibiotic	108213	7314	100899	93.2%	Reference
Acyclovir	36	4	32	88.9%	.4
Amantadine	308	15	293	95.1%	.2
Lopinavir-Ritonavir	99	25	74	74.7%	<.001
Oseltamivir	8324	2310	6014	72.2%	<.001
Rimantadine	59	7	52	88.1%	.1
Zanamivir	39	8	31	79.5%	.001
Antibiotic only	13300	1945	11355	85.4%	<.001
Treatment with oseltamivir					
No antiviral / Antibiotic	108213	7314	100899	93.2%	Reference
Oseltamivir	3738	1032	2706	72.4%	<.001
Antibiotic only	13300	1945	11355	85.4%	<.001
Oseltamivir + Antibiotic	4586	1278	3308	72.1%	<.001
Data expressed as number of patients or percentual of survival. P values were calculated by Log-Rank test.					

Supplementary Table 7. Survival analysis of laboratory-confirmed COVID-19 children and adolescents treated with antivirals and/or antibiotics in 273 accredited medical units in Mexico City, between February 24, 2020 and September 14, 2020.

Group	Total	Deaths	Survivors	Survival	P value
Children and adolescents	5791	40	5751	99.31%	-
Type of treatment					
No antiviral/antibiotic	5336	28	5308	99.5%	Reference
Antiviral only	40	0	40	100.0%	.7
Antibiotic only	376	10	366	97.3%	<.0001
Antiviral + Antibiotic	39	2	37	94.9%	<.0001
Type of antiviral or antibiotic only					
No antiviral/antibiotic	5336	28	5308	99.5%	Reference
Amantadine	9	0	9	100.0%	.8
Lopinavir-Ritonavir	1	0	1	100.0%	.9
Oseltamivir	67	2	65	97.0%	.008
Rimantadine	2	0	2	100.0%	.9
Antibiotic only	376	10	366	97.3%	<.001
Treatment with oseltamivir					
No antiviral/antibiotic	5336	28	5308	99.5%	Reference
Oseltamivir	36	0	36	100.0%	.7
Antibiotic only	376	10	366	97.3%	<.001
Oseltamivir + Antibiotic	31	2	29	93.5%	<.001
Data expressed as number of patients or percentual of survival. P values were calculated by Log-Rank test.					

Supplementary Table 8. Survival analysis of laboratory-confirmed COVID-19 pregnant women treated with antivirals and/or antibiotics in 177 accredited medical units in Mexico City, between February 24, 2020 and September 14, 2020.

Group	Total	Deaths	Survivors	Survival	P value
Pregnancy	581	10	571	98.3%	-
Type of treatment					
No antiviral / Antibiotic	530	8	522	98.5%	Reference
Antiviral only	12	1	11	91.7%	.07
Antibiotic only	35	0	35	100.0%	.9
Antiviral + Antibiotic	6	1	5	83.3%	.004
Type of antiviral					
No antiviral / antibacterial agent	530	8	522	98.5%	Reference
Amantadine	2	0	2	100.0%	.9
Oseltamivir	16	2	14	87.5%	.001
Antibacterial agent only	35	0	35	100.0%	.5
Treatment with Oseltamivir					
No antiviral / Antibiotic	530	8	522	98.5%	Reference
Oseltamivir	11	1	10	90.9%	.05
Antibiotic only	35	0	35	100.0%	.5
Oseltamivir + Antibiotic	5	1	4	80.0%	.001
Data expressed as number of patients or percentual of survival. P values were calculated by Log-Rank test.					

Supplementary Table 9. Unadjusted Cox regression models for mortality risk in laboratory-confirmed COVID-19 patients receiving antivirals, antibiotics, both, or none in accredited COVID-19 medical units in Mexico City.

	All patients		Ambulatory		Hospitalized		Non-Critical		Critical	
	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P	HR (95%CI)	P
Models for type of treatment										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Antiviral only	4.43 (4.15-4.72)	<.001	7.48 (6.29-8.90)	<.001	1.19 (1.11-1.27)	<.001	5.07 (4.67-5.52)	<.001	1.21 (1.09-1.34)	<.001
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.79 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.58-0.67)	<.001
Antiviral + antibiotic	4.31 (4.05-4.58)	<.001	4.02 (3.09-5.22)	<.001	0.90 (0.85-0.96)	.001	4.65 (4.29-5.05)	<.001	0.96 (0.88-1.05)	.4
Models for type of antiviral										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Acyclovir	1.71 (0.64-4.56)	.3	Not estimable		1.68 (0.63-4.48)	.3	1.51 (0.38-6.07)	.6	1.51 (0.38-6.03)	.6
Amantadine	0.71 (0.43-1.17)	.2	1.06 (0.34-3.29)	.9	0.77 (0.44-1.36)	.4	0.68 (0.34-1.36)	.3	0.85 (0.40-1.78)	.7
Lopinavir-Ritonavir	3.90 (2.61-5.83)	<.001	12.96 (1.83-92.15)	.01	0.57 (0.38-0.85)	.006	2.69 (1.28-5.65)	.009	0.57 (0.36-0.90)	.02
Oseltamivir	4.57 (4.36-4.79)	<.001	6.55 (5.63-7.63)	<.001	1.01 (0.97-1.07)	.6	5.12 (4.81-5.46)	<.001	1.07 (0.99-1.14)	.08
Rimantadine	1.74 (0.84-3.68)	0.1	2.02 (0.28-14.36)	.5	1.19 (0.54-2.65)	.7	1.83 (0.69-4.89)	.2	1.77 (0.57-5.48)	.3
Zanamivir	3.22 (1.61-6.44)	.001	5.24 (0.73-37.23)	.09	0.76 (0.36-1.60)	.5	2.34 (0.76-7.27)	.1	1.18 (0.49-2.85)	.7
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.79 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.59-0.67)	<.001
Models for Acyclovir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Acyclovir only	2.16 (0.30-15.31)	.4	Not estimable		4.09 (0.58-29.05)	.2	Not estimable		2.21 (0.31-15.68)	.4
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.78 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.58-0.67)	<.001
Acyclovir + antibiotic	1.60 (0.52-4.97)	.4	Not estimable		1.41 (0.45-4.37)	.6	1.85 (0.46-7.38)	.4	1.16 (0.16-8.24)	.9
Models for Amantadine										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Amantadine only	1.17 (0.68-2.02)	.6	1.34 (0.34-5.38)	.7	1.47 (0.82-2.66)	.2	1.15 (0.55-2.42)	.7	1.12 (0.50-2.50)	.8
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.79 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.58-0.67)	<.001
Amantadine + antibiotic	0.19 (0.05-0.08)	.02	0.74 (0.10-5.27)	.8	0.13 (0.09-0.88)	.04	0.18 (0.03-1.25)	.08	0.34 (0.05-2.44)	.3
Models for Lopinavir-Ritonavir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Lopinavir-Ritonavir only	2.79 (1.05-7.44)	.04	4.24.97 (59.62-3029.30)	<.001	0.38 (0.14-1.00)	.05	1.91 (0.27-13.63)	.5	0.36 (0.14-0.96)	.04
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.79 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.58-0.67)	<.001
Lopinavir-Ritonavir + antibiotic	4.24 (2.73-6.58)	<.001	Not estimable		0.64 (0.41-0.99)	.04	2.88 (1.29-6.42)	.01	0.67 (0.39-1.14)	.1

Models for Oseltamivir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Oseltamivir only	4.62 (4.33-4.94)	<.001	8.00 (6.71-9.54)	<.001	1.20 (1.12-1.29)	<.001	5.36 (4.92-5.83)	<.001	1.24 (1.12-1.37)	<.001
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.79 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.59-0.67)	<.001
Oseltamivir + antibiotic	4.53 (4.26-4.82)	<.001	4.56 (3.51-5.94)	<.001	0.91 (0.86-0.97)	.003	4.92 (4.54-5.35)	<.001	0.97 (0.89-1.06)	.5
Models for Rimantadine										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Rimantadine only	2.75 (1.24-6.12)	.01	4.09 (0.58-29.09)	.2	1.21 (0.50-2.90)	.7	2.54 (0.82-7.88)	.1	1.79 (0.58-5.55)	.3
Antibiotic only	2.15 (2.05-2.27)	<.001	1.09 (0.88-1.36)	.4	0.78 (0.75-0.83)	<.001	1.88 (1.75-2.03)	<.001	0.63 (0.58-0.67)	<.001
Rimantadine + antibiotic	0.55 (0.08-3.91)	.6	Not estimable		1.14 (0.16-8.06)	.9	0.99 (0.14-7.08)	.9	-	-
Models for Zanamivir										
No antiviral / antibiotic	Reference		Reference		Reference		Reference		Reference	
Zanamivir only	3.91 (1.75-8.69)	.001	10.31 (1.45-73.28)	.02	0.78 (0.33-1.88)	.6	1.40 (0.19-9.96)	.7	1.19 (0.49-2.86)	.7
Antibiotic only	2.15 (2.05-2.28)	<.001	1.09 (0.88-1.36)	.4	0.79 (0.75-0.83)	<.001	1.89 (1.75-2.03)	<.001	0.63 (0.49-2.86)	<.001
Zanamivir + antibiotic	2.11 (0.53-8.43)	.3	Not estimable		0.72 (0.18-2.87)	.6	3.52 (0.88-14.1)	.07	-	-
HR: Hazard ratio, 95%CI: 95% confidence intervals										

Supplementary Table 10. Mortality risk in laboratory-confirmed COVID-19 patients who underwent invasive mechanical ventilation (IMV) and were treated with antivirals and/or antibiotics in one of 197 accredited hospitals in Mexico City, between February 24, 2020 and September 14, 2020

	Unadjusted model		Adjusted model ^a	
	HR (95% CI)	P value	HR (95% CI)	P value
Type of treatment				
No antiviral/antibiotic	Reference		Reference	
Antiviral only	1.18 (1.07-1.31)	.001	1.13 (1.02-1.25)	.02
Antibiotic only	0.62 (0.59-0.67)	<.001	0.64 (0.60-0.69)	<.001
Antiviral + antibiotic	0.95 (0.88-1.04)	.3	0.98 (0.90-1.07)	.7
Type of antiviral				
No antiviral/antibiotic	Reference		Reference	
Acyclovir	1.42 (0.36-5.68)	.6	1.96 (0.49-7.83)	.3
Amantadine	1.29 (0.61-2.70)	.5	1.29 (0.61-2.72)	.5
Lopinavir-Ritonavir	0.67 (0.41-1.09)	.1	0.68 (0.42-1.12)	.1
Oseltamivir	1.04 (0.97-1.12)	.3	1.04 (0.97-1.12)	.2
Rimantadine	1.66 (0.53-5.14)	.4	1.57 (0.50-4.90)	.4
Zanamivir	1.09 (0.48-2.64)	.8	0.87 (0.36-2.09)	.8
Antibiotic only	0.63 (0.59-0.67)	<.001	0.64 (0.60-0.69)	<.001
Acyclovir				
No antiviral/antibiotic	Reference		Reference	
Acyclovir only	2.09 (0.29-14.9)	.5	2.85 (0.40-20.35)	.3
Antibiotic only	0.63 (0.58-0.67)	<.001	0.64 (0.60-0.69)	<.001
Acyclovir + antibiotic	1.09 (0.15-7.74)	.9	1.52 (0.21-10.78)	.7
Amantadine				
No antiviral/antibiotic	Reference		Reference	
Amantadine only	1.51 (0.68-3.35)	.3	1.50 (0.67-3.35)	.32
Antibiotic only	0.63 (0.58-0.67)	<.001	0.64 (0.6-0.69)	<.001
Amantadine + antibiotic	0.71 (0.09-5.01)	.7	0.71 (0.10-5.09)	.7

Lopinavir-Ritonavir				
No antiviral/antibiotic	Reference		Reference	
Lopinavir-Ritonavir only	0.59 (0.19-1.86)	.4	0.53 (0.17-1.63)	.3
Antibiotic only	0.63 (0.58-0.67)	<.001	0.64 (0.60-0.69)	<.001
Lopinavir-Ritonavir + antibiotic	0.68 (0.39-1.17)	.2	0.74 (0.43-1.27)	.3
Oseltamivir				
No antiviral/antibiotic	Reference		Reference	
Oseltamivir only	1.19 (1.07-1.31)	.001	1.14 (1.02-1.26)	.02
Antibiotic only	0.63 (0.59-0.67)	<.001	0.64 (0.60-0.69)	<.001
Oseltamivir + antibiotic	0.96 (0.88-1.05)	.4	0.99 (0.91-1.08)	.8
Rimantadine				
No antiviral/antibiotic	Reference		Reference	
Rimantadine only	1.68 (0.54-5.20)	.4	1.66 (0.53-5.17)	.4
Antibiotic only	0.63 (0.58-0.67)	<.001	0.64 (0.60-0.69)	<.001
Zanamivir				
No antiviral/antibiotic	Reference		Reference	
Zanamivir only	1.10 (0.46-2.66)	.8	0.87 (0.36-2.10)	.8
Antibiotic only	0.63 (0.58-0.67)	<.001	0.64 (0.60-0.69)	<.001
HR: Hazard ratio, 95%CI: 95% confident interval.				
a: Models adjusted by: Sex (men), Age, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Cardiovascular disease, Chronic kidney disease, Smoker, Unemployed, Irritability, Headache, Myalgias, Arthralgias, Rhinorrhea, Abdominal pain, Cyanosis.				

Supplementary Table 11. Mortality risk in laboratory-confirmed COVID-19 patients who were treated with antivirals and/or antibiotics and admitted to one of 125 accredited intensive care units (ICU) in Mexico City, between February 24, 2020 and September 14, 2020

	Unadjusted model		Adjusted model ^a	
	HR (95% CI)	P value	HR (95% CI)	P value
Type of treatment				
No antiviral/antibiotic	Reference		Reference	
Antiviral only	1.60 (1.21-2.13)	.001	1.42 (1.07-1.89)	.02
Antibiotic only	1.15 (1.02-1.29)	.02	1.05 (0.93-1.19)	.4
Antiviral + antibiotic	1.71 (1.49-1.97)	<.001	1.49 (1.30-1.72)	<.001
Type of antiviral				
No antiviral/antibiotic	Reference		Reference	
Acyclovir	5.33 (0.75-37.9)	.09	8.38 (1.16-60.62)	.04
Amantadine	Not estimable		Not estimable	
Lopinavir-Ritonavir	1.21 (0.75-1.97)	.44	0.99 (0.61-1.61)	.9
Oseltamivir	1.74 (1.52-1.96)	<.001	1.52 (1.33-1.74)	<.001
Antibiotic only	1.15 (1.02-1.29)	.02	1.05 (0.93-1.18)	.4
Acyclovir				
No antiviral/antibiotic	Reference		Reference	
Acyclovir only	5.46 (0.77-38.9)	.09	10.21 (1.40-74.38)	.02
Antibiotic only	1.15 (1.02-1.29)	.02	1.05 (0.93-1.18)	.4
Amantadine				
No antiviral/antibiotic	Reference		Reference	
Amantadine only	Not estimable		Not estimable	
Antibiotic only	1.15 (1.02-1.29)	.02	1.05 (0.93-1.18)	.4
Amantadine + antibiotic	Not estimable		Not estimable	
Lopinavir-Ritonavir				
No antiviral/antibiotic	Reference		Reference	
Lopinavir-Ritonavir only	0.74 (0.28-1.98)	.6	0.50 (0.19-1.35)	.2

Antibiotic only	1.15 (1.02-1.29)	.0	1.05 (0.93-1.18)	.5
Lopinavir-Ritonavir + antibiotic	1.50 (0.89-2.61)	.2	1.32 (0.76-2.29)	.3
Oseltamivir				
No antiviral/antibiotic	Reference		Reference	
Oseltamivir only	1.79 (1.34-2.42)	<.001	1.64 (1.22-2.21)	<.001
Antibiotic only	1.15 (1.02-1.29)	.02	1.05 (0.93-1.19)	.4
Oseltamivir + antibiotic	1.73 (1.51-1.99)	<.001	1.50 (1.30-1.73)	<.001
HR: Hazard ratio, 95%CI: 95% confident interval.				
a: Models adjusted by: Sex (men), Age, Diabetes, Chronic obstructive pulmonary disease, Hypertension, Obesity, Chronic kidney disease, Unemployed, Fever, Cough, Shortness of breath, Myalgias, Vomit, Cyanosis				

Supplementary Table 12. Mortality risk in laboratory-confirmed COVID-19 non-pregnant/puerperal adults treated with antivirals and/or antibiotics in 379 accredited medical units in Mexico City, between February 24, 2020 and September 14, 2020.

	Unadjusted model		Adjusted model ^a	
	HR (95% CI)	P value	HR (95% CI)	P value
Type of treatment				
No antiviral/antibiotic	Reference		Reference	
Antiviral only	4.34 (4.07-4.62)	<.001	1.80 (1.68-1.92)	<.001
Antibiotic only	2.18 (2.08-2.29)	<.001	1.19 (1.13-1.25)	<.001
Antiviral + antibiotic	4.31 (4.07-4.57)	<.001	1.64 (1.54-1.74)	<.001
Type of antiviral				
No antiviral/antibiotic	Reference		Reference	
Acyclovir	1.57 (0.59-4.18)	.4	1.40 (0.52-3.72)	.5
Amantadine	0.69 (0.42-1.16)	.2	0.72 (0.43-1.20)	.2
Lopinavir-Ritonavir	3.88 (2.62-5.74)	<.001	1.14 (0.77-1.69)	.5
Oseltamivir	4.52 (4.32-4.74)	<.001	1.73 (1.65-1.82)	<.001
Rimantadine	1.75 (0.83-3.67)	.1	1.47 (0.70-3.08)	.3
Zanamivir	3.04 (1.52-6.08)	.002	1.61 (0.81-3.22)	.2
Antibiotic only	2.18 (2.08-2.29)	<.001	1.19 (1.13-1.25)	<.001
Acyclovir				
No antiviral/antibiotic	Reference		Reference	
Acyclovir only	2.09 (0.29-14.8)	.5	7.50 (1.06-53.27)	.04
Antibiotic only	2.18 (2.08-2.29)	<.001	1.16 (1.10-1.22)	<.001
Acyclovir + antibiotic	1.45 (0.46-4.48)	.5	1.11 (0.36-3.45)	.9
Amantadine				
No antiviral/antibiotic	Reference		Reference	
Amantadine only	1.15 (0.67-1.98)	.6	1.75 (1.02-3.02)	.04
Antibiotic only	2.18 (2.08-2.29)	<.001	1.16 (1.10-1.22)	<.001
Amantadine + antibiotic	0.19 (0.05-0.78)	.02	0.15 (0.04-0.59)	.007

Lopinavir-Ritonavir				
No antiviral/antibiotic	Reference		Reference	
Lopinavir-Ritonavir only	3.27 (1.36-7.88)	.008	0.83 (0.34-1.99)	.7
Antibiotic only	2.18 (2.08-2.29)	<.001	1.16 (1.11-1.22)	<.001
Lopinavir-Ritonavir + antibiotic	4.06 (2.62-6.29)	<.001	1.18 (0.76-1.83)	.5
Oseltamivir				
No antiviral/antibiotic	Reference		Reference	
Oseltamivir only	4.52 (4.24-4.83)	<.001	1.81 (1.69-1.93)	<.001
Antibiotic only	2.18 (2.08-2.29)	<.001	1.19 (1.13-1.25)	<.001
Oseltamivir + antibiotic	4.52 (4.26-4.79)	<.001	1.68 (1.58-1.78)	<.001
Rimantadine				
No antiviral/antibiotic	Reference		Reference	
Rimantadine only	2.71 (1.22-6.03)	.02	2.02 (0.91-4.50)	.1
Antibiotic only	2.18 (2.08-2.29)	<.001	1.16 (1.11-1.22)	<.001
Rimantadine + antibiotic	0.56 (0.08-3.97)	.6	0.53 (0.07-3.77)	.5
Zanamivir				
No antiviral/antibiotic	Reference		Reference	
Zanamivir only	3.79 (1.71-8.45)	.001	2.02 (0.91-4.50)	.1
Antibiotic only	2.18 (2.08-2.29)	<.001	1.16 (1.11-1.22)	<.001
Zanamivir + antibiotic	1.90 (0.48-7.62)	.36	0.97 (0.24-3.86)	.9
HR: Hazard ratio, 95%CI: 95% confident interval.				
a: Models adjusted by: Sex (men), Age, Diabetes, Chronic obstructive pulmonary disease, Immunosuppression, Hypertension, Human immunodeficiency virus/acquired immune deficiency syndrome, Obesity, Cardiovascular disease, Chronic kidney disease, Smoker, Unemployed, Fever, Cough, Shortness of breath, Irritability, Chest pain, Myalgias, Arthralgias, Polypnea, Vomit, Abdominal pain.				

Supplementary Table 13. Mortality risk in laboratory-confirmed COVID-19 children and adolescents treated with antivirals and/or antibiotics in 273 accredited medical units in Mexico City, between February 24, 2020 and September 14, 2020

	Unadjusted model		Adjusted model ^a	
	HR (95% CI)	P value	HR (95% CI)	P value
Type of treatment				
No antiviral/antibiotic	Reference		Reference	
Antiviral only	Not estimable		Not estimable	
Antibiotic only	5.01 (2.43-10.32)	<.001	4.22 (2.01-8.86)	<.001
Antiviral + antibiotic	9.68 (2.31-40.62)	.002	6.54 (1.44-29.63)	.01
Type of antiviral				
No antiviral/antibiotic	Reference		Reference	
Amantadine	Not estimable		Not estimable	
Lopinavir-Ritonavir	Not estimable		Not estimable	
Oseltamivir	5.66 (1.35-23.73)	.02	4.22 (0.94-18.99)	.06
Rimantadine	Not estimable		Not estimable	
Antibiotic only	5.01 (2.43-10.31)	<.001	4.20 (2.00-8.83)	<.001
Oseltamivir				
No antiviral/antibiotic	Reference		Reference	
Oseltamivir only	Not estimable		Not estimable	
Antibiotic only	5.01 (2.43-10.3)	<.001	4.20 (2.00-8.82)	<.001
Oseltamivir + antibiotic	12.10 (2.89-50.84)	.001	7.95 (1.70-37.21)	.01
HR: Hazard ratio, 95%CI: 95% confident interval.				
a: Models adjusted by: Diabetes, Immunosuppression, Chronic kidney disease.				

Supplementary Table 14. Mortality risk in laboratory-confirmed COVID-19 pregnant women treated with antivirals and/or antibiotics in 117 accredited medical units in Mexico City, between February 24, 2020 and September 14, 2020.

	Unadjusted model	
	HR (95% CI)	P value
Type of treatment		
No antiviral/antibiotic	Reference	
Antiviral only	5.51 (0.69-44.06)	.1
Antibiotic only	Not estimable	
Antiviral + antibiotic	11.14 (1.39-89.07)	.02
Type of antiviral		
No antiviral/antibiotic	Reference	
Amantadine	Not estimable	
Oseltamivir	8.35 (1.77-39.30)	.007
Antibiotic only	Not estimable	
Oseltamivir		
No antiviral/antibiotic	Reference	
Oseltamivir only	6.04 (0.76-48.26)	.09
Antibiotic only	Not estimable	
Oseltamivir + antibiotic	13.52 (1.69-108.10)	.01
HR: Hazard ratio, 95%CI: 95% confident interval.		

Supplementary Table 15. E-Values for Cox regression models in the general population, ambulatory, hospitalized, non-critical, and critical COVID-19 patients.

	All patients	Ambulatory	Hospitalized	Non-Critical	Critical
Models for type of treatment used					
Antiviral only	2.83 (2.60)	8.87 (7.34)	-	3.48 (3.12)	-
antibiotic only	1.51 (1.37)	2.12 (1.5)	1.77 (1.60)	-	2.35 (2.12)
Antiviral + antibiotic	2.52 (2.30)	3.23 (2.3)	1.43 (1.21)	2.64 (2.34)	-
Models for type of antiviral used					
Acyclovir	-	-	4.94 (1.21)	-	-
Amantadine	-	-	-	-	-
Lopinavir-Ritonavir	-	-	2.78 (1.5)	-	-
Oseltamivir	2.71 (2.54)	6.50 (5.47)	-	3.08 (2.83)	-
Rimantadine	-	-	-	-	-
Zanamivir	-	-	-	-	-
Antibiotic only	1.54 (1.37)	2.12 (1.46)	1.77 (1.60)	-	2.30 (2.12)
Models for Acyclovir					
Acyclovir only	15.68 (1.54)	-	17.45 (1.83)	-	-
antibiotic only	1.46 (1.28)	2.17 (1.5)	1.74 (1.60)	-	2.35 (2.12)
Acyclovir + antibiotic	-	-	-	-	-
Models for Amantadine					
Amantadine only	2.96 (1.21)	-	-	-	-
antibiotic only	1.46 (1.28)	2.17 (1.50)	1.74 (1.60)	-	2.35 (2.12)
Amantadine + antibiotic	12.81 (2.78)	-	-	14.87 (1.46)	-
Models for Lopinavir-Ritonavir					
Lopinavir-Ritonavir only	-	113 (15.22)	-	-	-
antibiotic only	1.46 (1.28)	2.17 (1.50)	1.74 (1.60)	-	2.35 (2.12)
Lopinavir-Ritonavir + antibiotic	-	-	-	-	-
Models for Oseltamivir					
Oseltamivir only	2.83 (2.60)	9.05 (7.48)	-	3.52 (3.17)	-
antibiotic only	1.51 (1.37)	2.12 (1.50)	1.74 (1.60)	-	2.35 (2.12)
Oseltamivir + antibiotic	2.60 (2.39)	3.62 (2.69)	1.39 (1.16)	2.75 (2.47)	-
Models for Rimantadine					
Rimantadine only	-	-	-	-	-
antibiotic only	1.46 (1.28)	2.17 (1.50)	1.74 (1.60)	-	2.35 (2.12)

Rimantadine + antibiotic	-	-	-	-	-
Models for Zanamivir					
Zanamivir only	-	-	-	-	-
antibiotic only	1.46 (1.28)	2.17 (1.50)	1.74 (1.60)	-	2.35 (2.12)
Zanamivir + antibiotic	-	-	-	-	-
Data presented as E-value for point estimate (E-value for lower-limit confidence interval)					

Supplementary Table 16. E-Values for Cox regression models in the non-pregnant/puerperal adults, children and adolescents, VMI and ICU COVID-19 patients.

	IMV	ICU	Non-pregnant/puerperal adults	Children and adolescents
Models for type of treatment used				
Antiviral only	1.51 (1.16)	2.19 (1.34)	3.00 (2.75)	-
Antibiotic only	2.50 (2.26)	-	1.67 (1.51)	7.91 (3.43)
Antiviral + antibiotic	-	2.34 (1.92)	2.66 (2.45)	12.56 (2.24)
Models for type of antiviral used				
Acyclovir	-	16.24 (1.59)	-	-
Amantadine	-	-	-	-
Lopinavir-Ritonavir	-	-	-	-
Oseltamivir	-	2.41 (1.99)	2.85 (2.69)	-
Rimantadine	-	-	-	-
Zanamivir	-	-	-	-
Antibiotic only	2.50 (2.26)	-	1.67 (1.51)	7.87 (3.41)
Models for Acyclovir				
Acyclovir only	-	19.91 (2.15)	14.48 (1.31)	-
Antibiotic only	2.50 (2.26)	-	1.59 (1.43)	-
Acyclovir + antibiotic	-	-	-	-
Models for Amantadine				
Amantadine only	-	-	2.9 (1.16)	-
Antibiotic only	2.50 (2.26)	-	1.59 (1.43)	-
Amantadine + antibiotic	-	-	-	-
Models for Lopinavir-Ritonavir				
Lopinavir-Ritonavir only	-	-	-	-
Antibiotic only	2.50 (2.26)	-	1.59 (1.43)	-
Lopinavir-Ritonavir + antibiotic	-	-	-	-
Models for Oseltamivir				
Oseltamivir only	1.54 (1.16)	2.66 (1.74)	3.02 (2.77)	-
Antibiotic only	2.50 (2.26)	-	1.67 (1.51)	7.87 (3.41)
Oseltamivir + antibiotic	-	2.37 (1.92)	2.75 (2.54)	15.38 (2.79)
Data presented as E-value for point estimate (E-value for lower-limit confidence interval)				

Supplementary Tabla 17. Baseline characteristics of 903 patients with data of timing of initiation of antiviral treatment with laboratory-confirmed COVID-19, who received medical attention in one of 154 accredited medical units in Mexico City.

	Total n=903	Acyclovir n=26	Amantadine n=131	Lopinavir- Ritonavir n=9	Oseltamivir n=702	Rimantadine n=24	Zinamivir n=11
Sex							
Women	403 (44.6)	14 (53.8)	72 (55)	2 (22.2)	294 (41.9)	13 (54.2)	8 (72.7)
Men	500 (55.4)	12 (46.2)	59 (45)	7 (77.8)	408 (58.1)	11 (45.8)	3 (27.3)
Age, mean (SD)	46.7 (14.8)	44.5 (13.9)	42.3 (14.3)	51 (11.1)	47.8 (14.8)	42.6 (13.9)	40 (13.9)
Age categories							
0-19 years	17 (1.9)	0 (0)	5 (3.8)	0 (0)	11 (1.6)	1 (4.2)	0 (0)
20-29 years	88 (9.7)	5 (19.2)	18 (13.7)	0 (0)	62 (8.8)	1 (4.2)	2 (18.2)
30-39 years	204 (22.6)	5 (19.2)	40 (30.5)	0 (0)	147 (20.9)	8 (33.3)	4 (36.4)
40-49 years	220 (24.4)	7 (26.9)	26 (19.8)	5 (55.6)	170 (24.2)	10 (41.7)	2 (18.2)
50-59 years	192(21.3)	4 (15.4)	25 (19.1)	2 (22.2)	157 (22.4)	2 (8.3)	2 (18.2)
60-69 years	118 (13.1)	5 (19.2)	11 (8.4)	1 (11.1)	100 (14.2)	0 (0)	1 (9.1)
70-79 years	51 (5.6)	0 (0)	5 (3.8)	1 (11.1)	43 (6.1)	2 (8.3)	0 (0)
80-89 years	10 (1.1)	0 (0)	1 (0.8)	0 (0)	9 (1.3)	0 (0)	0 (0)
90-99 years	3 (0.3)	0 (0)	0 (0)	0 (0)	3 (0.4)	0 (0)	0 (0)
Indigenous self-identification	10 (1.1)	0 (0)	1 (0.8)	0 (0)	7 (1)	0 (0)	2 (18.2)
Occupation							
Technical services	29 (3.2)	0 (0)	3 (2.3)	0 (0)	25 (3.6)	0 (0)	1 (9.1)
Education	34 (3.8)	0 (0)	8 (6.1)	0 (0)	25 (3.6)	1 (4.2)	0 (0)
Healthcare	117 (13)	2 (7.7)	12 (9.2)	2 (22.2)	97 (13.8)	4 (16.7)	0 (0)
Agricultural activities	2 (0.2)	0 (0)	0 (0)	0 (0.0)	2 (0.3)	0 (0)	0 (0)
Commerce	327 (36.2)	12 (46.2)	53 (40.5)	0 (0.0)	251 (35.8)	8 (33.3)	3 (27.3)
Other	197 (21.8)	5 (19.2)	31 (23.7)	6 (66.7)	149 (21.2)	5 (20.8)	1 (9.1)
Unemployed	17 (1.9)	0 (0)	0 (0)	1 (11.1)	15 (2.1)	1 (4.2)	0 (0)
Stay-at-home	180 (19.9)	7 (26.9)	24 (18.3)	0 (0)	138 (19.7)	5 (20.8)	6 (54.5)
Last-season flu vaccination	222 (24.6)	5 (19.2)	38 (29)	1 (11.1)	173 (24.6)	4 (16.7)	1 (9.1)
Special populations							
Children and adolescents (<18 years)	11 (1.2)	0 (0.0)	3 (2.3)	0 (0)	7 (1)	1 (4.2)	0 (0)
Age, mean (SD)	11.6 (5.5)	-	11 (7.8)	-	11.9 (5.5)	12	-
Last-season flu vaccination	2 (18.2)	0 (0)	0 (0)	0 (0)	2 (28.6)	0 (0)	0 (0)
Non-pregnant/puerperal adults (≥18 years)	890 (98.6)	26 (100)	128 (97.7)	9 (100)	693 (98.7)	23 (95.8)	11 (100)

Age, mean (SD)	47.2 (14.3)	44.5 (13.9)	42.9 (13.6)	51 (11.1)	48.2 (14.2)	43.9 (12.6)	40 (12.9)
Last-season flu vaccination	220 (24.7)	5 (19.2)	38 (29.7)	1 (11.1)	171 (24.7)	4 (17.4)	1 (9.1)
Comorbidities							
Diabetes	138 (15.3)	0 (0)	10 (7.6)	2 (22.2)	123 (17.5)	3 (12.5)	0 (0)
COPD	12 (1.3)	0 (0)	2 (1.5)	0 (0)	10 (1.4)	0 (0)	0 (0)
Asthma	23 (2.5)	1 (3.8)	3 (2.3)	1 (11.1)	18 (2.6)	0 (0)	0 (0)
Immunosuppression	14 (1.6)	0 (0)	5 (3.8)	0 (0)	9 (1.3)	0 (0)	0 (0)
Hypertension	166 (18.4)	4 (15.4)	11 (8.4)	0 (0)	147 (20.9)	3 (12.5)	1 (9.1)
HIV/AIDS	2 (0.2)	0 (0)	0 (0)	0 (0)	2 (0.3)	0 (0)	0 (0)
Cardiovascular disease	27 (1.6)	2 (7.7)	1 (0.8)	1 (11.1)	23 (3.3)	0 (0)	0 (0)
Obesity	241 (3)	9 (34.6)	41 (31.3)	2 (22.2)	182 (25.9)	3 (12.5)	4 (36.4)
Chronic kidney disease	17 (26.7)	0 (0)	0 (0)	0 (0)	17 (2.4)	0 (0)	0 (0)
Smoker	107 (1.9)	0 (0)	20 (15.3)	1 (11.1)	82 (11.7)	2 (8.3)	2 (18.2)
Type of medical attention							
Ambulatory	675 (74.8)	26 (100)	127 (96.9)	0 (0)	491 (69.9)	22 (91.7)	9 (81.8)
Hospitalization	228 (25.2)	0 (0)	4 (3.1)	9 (10)	211 (30.1)	2 (8.3)	2 (18.2)
Severity of the disease							
Non-critical	833 (92.2)	26 (100)	130 (99.2)	4 (44.4)	638 (90.9)	24 (100)	11 (100)
Critical	70 (7.8)	0 (0)	1 (0.8)	5 (55.6)	64 (9.1)	0 (0)	0 (0)
Baseline symptoms							
Fever	643 (71.2)	20 (76.9)	82 (62.6)	9 (100)	511 (72.8)	12 (50)	9 (81.8)
Cough	675 (74.8)	17 (65.4)	98 (74.8)	7 (77.8)	527 (75.1)	17 (70.8)	9 (81.8)
Sore throat	434 (48.1)	10 (38.5)	63 (48.1)	3 (33.3)	338 (48.1)	14 (58.3)	6 (54.5)
Shortness of breath	402 (44.5)	11 (42.3)	36 (27.5)	6 (66.7)	335 (47.7)	9 (37.5)	5 (45.5)
Irritability	199 (22)	5 (19.2)	23 (17.6)	1 (11.1)	158 (22.5)	6 (25)	6 (54.5)
Diarrhea	285 (31.6)	9 (34.6)	39 (29.8)	1 (11.1)	226 (32.2)	4 (16.7)	6 (54.5)
Chest pain	330 (36.5)	8 (30.8)	37 (28.2)	3 (33.3)	266 (37.9)	9 (37.5)	7 (63.6)
Chills	434 (48.1)	12 (46.2)	60 (45.8)	3 (33.3)	342 (48.7)	11 (45.8)	6 (54.5)
Headache	645 (71.4)	19 (73.1)	93 (71)	7 (77.8)	502 (71.5)	15 (62.5)	9 (81.8)
Myalgias	590 (65.3)	20 (76.9)	78 (59.5)	5 (55.6)	464 (66.1)	15 (62.5)	8 (72.7)
Arthralgias	552 (61.1)	16 (61.5)	73 (55.7)	5 (55.6)	436 (62.1)	16 (66.7)	6 (54.5)
Abrupt deterioration	556 (61.6)	15 (57.7)	77 (58.8)	6 (66.7)	440 (62.7)	12 (50)	6 (54.5)
Rhinorrhea	294 (32.6)	5 (19.2)	45 (34.4)	1 (11.1)	229 (32.6)	10 (41.7)	4 (36.4)
Polypnea	171 (18.9)	3 (11.5)	22 (16.8)	1 (11.1)	141 (20.1)	2 (8.3)	2 (18.2)
Vomit	106 (11.7)	2 (7.7)	9 (6.9)	1 (11.1)	90 (12.8)	3 (12.5)	1 (9.1)
Abdominal pain	153 (16.9)	1 (3.8)	17 (13)	2 (22.2)	127 (18.1)	3 (12.5)	3 (27.3)
Conjunctivitis	157 (17.4)	4 (15.4)	20 (15.3)	1 (11.1)	123 (17.5)	5 (20.8)	4 (36.4)
Cyanosis	67 (7.4)	1 (3.8)	7 (5.3)	1 (11.1)	56 (8)	1 (4.2)	1 (9.1)

Sudden onset of symptoms	349 (38.6)	7 (26.9)	47 (35.9)	5 (55.6)	274 (3)	12 (50)	4 (36.4)
Concomitant use of antibiotics	566 (62.7)	22 (84.6)	84 (64.1)	5 (55.6)	434 (61.8)	15 (62.5)	6 (54.5)
Timing of antiviral treatment							
Before medical attention	783 (86.7)	19 (73.1)	121 (92.4)	7 (77.8)	603 (85.9)	23 (95.8)	10 (90.9)
After medical attention	120 (13.3)	7 (26.9)	10 (7.6)	2 (22.2)	99 (14.1)	1 (4.2)	1 (9.1)
≤2 days after symptom onset	579 (64.2)	8 (30.8)	99 (75.6)	1 (11.1)	448 (63.9)	16 (66.7)	7 (63.6)
>2 days after symptom onset	323 (35.8)	18 (69.2)	32 (24.4)	8 (88.9)	253 (36.1)	8 (33.3)	4 (36.4)



Data expressed as frequency (%) or mean (SD)

SD: Standard deviation, COPD: Chronic obstructive pulmonary disease, HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome.

Supplementary Table 18. Survival analysis of laboratory-confirmed COVID-19 patients according to early or late use of antivirals.

Group	Total	Deaths	Survivors	Survival	P value
Early use of antivirals (≤2 days)	579	64	515	88.9%	-
Type of antiviral					
No antiviral/antibiotic	114143	7351	106792	93.6%	Reference
Acyclovir	8	0	8	100%	.5
Amantadine	99	2	97	98%	.08
Lopinavir-Ritonavir	1	0	1	100%	.8
Oseltamivir	448	62	386	86.2%	<.001
Rimantadine	16	0	16	100%	.3
Zanamivir	7	0	7	100%	.5
Late use of antivirals (>2 days)	323	28	295	91.3%	-
Type of antiviral					
No antiviral/antibiotic	114143	7351	106792	93.6%	Reference
Acyclovir	18	0	18	100%	.3
Amantadine	32	1	31	96.9%	.4
Lopinavir-Ritonavir	8	2	6	75%	.03
Oseltamivir	253	15	228	90.1%	.04
Rimantadine	8	0	8	100%	.5
Zanamivir	4	0	4	100%	.6
Data expressed as number of patients or percentual of survival. P values were calculated by Log-Rank test.					

Supplementary Figure 1. Time from symptom onset to initiation of antivirals (A) and time from initiation of antivirals to hospitalization (B) in 903 patients with laboratory-confirmed COVID-19 receiving medical attention in one of 154 accredited medical units in Mexico City.



Supplementary Figure 2. Comparisons of hospitalization rates in 903 patients with laboratory-confirmed COVID-19 receiving medical attention in one of 154 accredited medical units in Mexico City who received early (≤ 2 days) or late (>2 days) antivirals.

